Spondyloarthritis & psoriatic arthritis
No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axial spondyloarthritis (axSpA): a post hoc analysis of six phase 3 trials
Authors' conclusion
Clinical efficacy of secukinumab vs. placebo at Week 16 was generally similar between older and younger patients with either r-axSpA or nr-axSpA.
Study context
- Population
- Patients with r-axSpA or nr-axSpA from the MEASURE 1–5 and PREVENT trials
- Participants
- 1,427 patients6 phase 3 trials
- Comparison
- Secukinumab 150/300 mg vs placebo, treatment effect compared between age <40 and ≥40 years
- Outcome
- Treatment effect of secukinumab vs placebo within each age subgroup and difference in treatment effect between younger vs older subgroups
- Follow-up
- Week 16
Methodological detailsMEASURE 1-5 and PREVENT, age subgroup analysis
- MEASURE 1-5 and PREVENT
- Age subgroup analysis
Pooled result
As reported in the abstract
Difference in treatment effect of secukinumab vs placebo, younger vs older patients
Difference in LSM, SF-36 treatment effect (r-axSpA)
2.2
P < 0.05
Younger vs Older
Difference in LSM, Berlin SIJ total edema score treatment effect (nr-axSpA)
- 1.2
P < 0.05
Younger vs Older
LSM, Total ASspi-MRI-a score treatment effect (nr-axSpA)
- 0.4
P < 0.05
Younger vs Older
Original publication
No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials. Arthritis Res Ther. Published 11 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →